Related Experiment Video
Updated: Mar 17, 2026
Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
Published on: May 30, 2025
Defeat mutant KRAS with synthetic lethality
Xiufeng Pang1, Mingyao Liu1,2
1a Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University , Shanghai , China.
Abstract:
Ras proteins are considered as the founding members of a large superfamily of small GTPases that control fundamental cellular functions. Mutationally activated RAS genes were discovered in human cancer cells more than 3 decades ago, but intensive efforts on Ras structure, biochemistry, function and signaling continue even now. Because mutant Ras proteins are inherently difficult to inhibit and have yet been therapeutically conquered, it was designated as "the Everest of oncogenes" in the cancer genome landscape, further promoting a "renaissance" in RAS research. Different paths to directly or indirectly targeting mutant Ras signaling are currently under investigation in the hope of finding an efficacious regimen. Inhibitors directly binding to KRASG12C to block its downstream signaling have been revealed, supporting the notion of Ras' druggability. An alternative indirect approach by targeting synthetic lethal interactors of mutant RAS is underway. We recently employed a synthetic lethal drug screen plus a combinatorial strategy using a panel of clinical agents and discovered that KRAS-mutant cancers were fragile to the combined inhibition of polo-like kinase 1 (Plk1) and RhoA/Rho kinase (ROCK). The combined regimen of BI-2536 (a Plk1 inhibitor) and fasudil (a ROCK inhibitor) promoted a significant inhibition of patient-derived lung cancer xenografts and prolonged the survival of LSL-KRASG12D mice. In this commentary, we will summarize the state-of-the art for the direction of synthetic lethality, and also speculate on the future development of this approach.
Insights
Targeting Ras proteins, crucial in cancer, is challenging. Researchers found that combining Plk1 and ROCK inhibitors effectively inhibits KRAS-mutant cancers and improves survival in preclinical models.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Genetics
Background:
- Ras proteins are key regulators of fundamental cellular functions.
- Mutated RAS genes are prevalent in human cancers, posing significant therapeutic challenges.
- Targeting Ras signaling remains a critical goal in cancer research, often referred to as "the Everest of oncogenes".
Purpose of the Study:
- To explore novel therapeutic strategies for KRAS-mutant cancers.
- To investigate the potential of targeting synthetic lethal interactors of mutant Ras.
- To evaluate the efficacy of combined inhibition of polo-like kinase 1 (Plk1) and RhoA/Rho kinase (ROCK) in preclinical cancer models.
Main Methods:
- Employed a synthetic lethal drug screen combined with a panel of clinical agents.
- Utilized a combinatorial strategy to identify vulnerabilities in KRAS-mutant cancers.
- Tested the combined regimen of BI-2536 (Plk1 inhibitor) and fasudil (ROCK inhibitor) in patient-derived lung cancer xenografts and LSL-KRASG12D mice.
Main Results:
- Discovered that KRAS-mutant cancers are sensitive to the combined inhibition of Plk1 and ROCK.
- The combination of BI-2536 and fasudil significantly inhibited patient-derived lung cancer xenografts.
- The combined regimen prolonged survival in LSL-KRASG12D mice, demonstrating therapeutic potential.
Conclusions:
- Combined inhibition of Plk1 and ROCK represents a promising synthetic lethal strategy for KRAS-mutant cancers.
- This approach offers a new avenue for targeting previously undruggable Ras proteins.
- Further development of this combinatorial therapy holds potential for improving outcomes in patients with KRAS-mutant cancers.
More Related Videos
07:40A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
Published on: May 27, 2021
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
Related Concept Videos
02:38The Ras Gene
Ras is a...
01:16In-vitro Mutagenesis
02:41Lethal Alleles
Lucien Cuénot discovered lethal alleles in 1905 while studying the inheritance of coat color in mice. The agouti gene is responsible for the color of the coat in mice. This gene codes for an agouti-signaling protein, which is responsible for melanin distribution in mammals. The wild-type allele gives rise to gray-brown coat color in mice, while the mutant allele gives rise to yellow coat color. In addition to coat color, the agouti gene is associated with the yellow...